Trastuzumab deruxtecan
Enhertu · Antibody-drug conjugate (HER2/DXd)
Emerging AKI/proteinuria reports — under-published.
Zanosar · STZ
Nitrosourea alkylator · approved 1982 · 10 citations · FAERS AKI reporting ROR 4.04 (95% CI 2.08–7.87, 9 AKI reports)
A classic cause of proximal tubular injury and Fanconi syndrome — glycosuria, phosphaturia, aminoaciduria, and renal tubular acidosis. Now confined to niche islet-cell and neuroendocrine settings, it endures as a defining teaching example of drug-induced proximal tubulopathy.
Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.
A glucose-mimicking nitrosourea that the proximal tubule eagerly takes up and pays for with Fanconi syndrome.
Atlas fields gathered in one place, each linked to the section with its full text and sources. Educational, not medical advice.
Signature lesion
Nephrotoxicity is the major dose-limiting toxicity; transient proteinuria, tubular dysfunction and azotemia are common and a sizable minority develop clinically significant renal impairment, though precise rates are not uniformly quantified. Reported rate: decrease in estimated glomerular filtration rate of at least 25% during treatment in 30% — 111 patients (27 prospective + 84 retrospective) with locally advanced or metastatic well-differentiated digestive… (Legoux 2021, PMID 33751987).Source: Legoux et al., Clin Res Hepatol Gastroenterol 2021
Tubular injury within weeks, worsening with cumulative dose.
Distilled from: “Within weeks of therapy; worsens with cumulative dose; abrupt AKI possible on re-challenge.”
Abrupt AKI can recur on re-challenge.
Tubular injury caught early — rising proteinuria or a falling GFR — often stabilizes when the dose is reduced or the drug is stopped, but advanced damage can be irreversible.PMID 11219485 (opens PubMed in a new tab)
Distilled from the agent's cited literature — educational, not a substitute for the primary sources.
Recovery across agentsThis agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.
Global failure of proximal tubule reabsorption — glucosuria, phosphaturia and acidosis, classically from ifosfamide.
Direct death of tubular epithelial cells — the dose-limiting lesion of the platinums and zoledronate.
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Tap a signature to trace where it strikes the nephron.
Representative incidence
Fanconi Syndrome strikes: Proximal Tubule.
Fanconi Syndrome
Global failure of proximal tubule reabsorption — glucosuria, phosphaturia and acidosis, classically from ifosfamide.
Glucosamine-nitrosourea that alkylates DNA (and depletes NAD+ via PARP activation) and is preferentially taken up by GLUT2-expressing cells, the basis of both its islet-cell selectivity and its proximal tubular toxicity. Used for metastatic islet cell (pancreatic neuroendocrine) tumors and malignant carcinoid.
Class-level context for the major non-renal toxicities of the Nitrosourea alkylator class.
Hematologic
Cytopenias, thrombosis, TMA
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
8 primary references — trials, cohorts, mechanism, and reviews. Single-patient case reports are listed separately below, graded by strength. Citation metadata via PubMed / NLM.
Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.
Single-patient and small-series reports, graded by evidentiary strength — A Strong (biopsy-proven plus a series and/or positive rechallenge), B Moderate, and C Limited (a single clinically-diagnosed case). Strongest first. Grades are inferred automatically from each report's abstract and journal — a heuristic ranking aid, not a formal quality appraisal.
Everything below is FAERS — adverse events someone chose to report, about 245 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.
Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-11-15.
What reporting says about this profile's documented lesions
Counted by the report's active-substance field, which FAERS fills almost only on reports received from 2013 on, so these figures describe reports since then, not the agent's whole history.
Reported with a death outcome
62 of 245 reports
Reported with hospitalization
85 of 245 reports
Reports per year
Reports received per year, 2015–2026 · most recent year is partial · 16 of the 245 reports predate 2015 and are not drawn.
Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-11-15.
Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.
General onco-nephrology references
Where Streptozocin sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.
Enhertu · Antibody-drug conjugate (HER2/DXd)
Emerging AKI/proteinuria reports — under-published.
Gleevec · BCR-ABL TKI
Fluid retention; rare Fanconi and AKI.
Pepaxto · Peptide-conjugated alkylator
Delivers melphalan intracellularly; BRIDGE supports a reduced 30 mg dose in moderate renal impairment.
Ifex · Oxazaphosphorine alkylator
Chloroacetaldehyde → Fanconi syndrome.
Vidaza · Hypomethylating agent
Proximal (type 2) RTA / Fanconi-like tubulopathy; overt AKI uncommon.
Aqupla · Platinum agent
Second-gen platinum with reduced renal toxicity vs cisplatin.
Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.
Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile. Agents sharing a number are tied on all three. An agent marked FAERS n/a has too few reports to test, so its place rests on severity and injury breadth alone.
A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.
The leading contributors to Streptozocin’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Streptozocin; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.
Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 54 clinical records among the 300 most-relevant of 305 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.